RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 151 filers reported holding RA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 16.18 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $6,620,000 | +1.5% | 137,886 | -0.8% | 0.00% | 0.0% |
| Q4 2019 | $6,523,000 | +62.7% | 138,988 | -18.0% | 0.00% | +100.0% |
| Q3 2019 | $4,008,000 | -15.7% | 169,502 | +7.1% | 0.00% | 0.0% |
| Q2 2019 | $4,756,000 | +53.4% | 158,200 | +14.3% | 0.00% | 0.0% |
| Q1 2019 | $3,100,000 | +118.8% | 138,415 | +77.9% | 0.00% | – |
| Q4 2018 | $1,417,000 | +45.6% | 77,818 | +44.8% | 0.00% | – |
| Q3 2018 | $973,000 | +103.6% | 53,759 | +12.1% | 0.00% | – |
| Q2 2018 | $478,000 | +73.8% | 47,962 | -7.5% | 0.00% | – |
| Q1 2018 | $275,000 | -13.5% | 51,826 | +38.4% | 0.00% | – |
| Q4 2017 | $318,000 | -41.3% | 37,443 | +1.0% | 0.00% | – |
| Q3 2017 | $542,000 | -23.8% | 37,085 | -2.2% | 0.00% | – |
| Q2 2017 | $711,000 | +38.9% | 37,932 | +57.7% | 0.00% | – |
| Q1 2017 | $512,000 | +148.5% | 24,051 | +77.4% | 0.00% | – |
| Q4 2016 | $206,000 | – | 13,558 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Novo Holdings A/S | 2,031,562 | $17,268,000 | 2.42% |
| NEA Management Company, LLC | 3,493,636 | $29,696,000 | 1.23% |
| VHCP Management II, LLC | 544,612 | $4,629,000 | 1.11% |
| RA Capital Management | 1,351,808 | $11,490,000 | 0.96% |
| Rock Springs Capital Management LP | 600,000 | $5,100,000 | 0.23% |
| Rhenman & Partners Asset Management AB | 108,451 | $922,000 | 0.12% |
| Tekla Capital Management LLC | 356,237 | $3,028,000 | 0.12% |
| ELLINGTON MANAGEMENT GROUP LLC | 34,900 | $297,000 | 0.05% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 79,150 | $673,000 | 0.03% |
| Candriam S.C.A. | 151,000 | $1,284,000 | 0.02% |